Dynavax Technologies Corporation (DVAX)

Dynavax's stock price has been significantly impacted by several events in the past six months. Sanofi announced an agreement to acquire Dynavax for approximately $2.2 billion, leading to a stock rally. Dynavax reported Q3 2025 earnings per share (EPS) of $0.21, exceeding estimates, and Q2 2025 EPS of $0.14, also beating forecasts. Analyst ratings have varied, with a consensus rating of "Hold" and an average target price of $24.33. COO David F. Novack sold 30,000 shares of Dynavax stock in December 2025. Dynavax faced engagement from activist investor Deep Track Capital, which advocated for a sharper focus on HEPLISAV-B commercialization and increased share repurchases.

There is no explicit information detailing specific demand seasonality for Dynavax's products and services. Vaccine demand can be influenced by public health campaigns, disease outbreaks, and policy changes, but a clear seasonal pattern for HEPLISAV-B or CpG 1018 is not specified.

Dynavax Technologies Corporation is a commercial-stage biopharmaceutical company focused on developing and commercializing novel vaccines to prevent infectious diseases. Their flagship product is HEPLISAV-B, an adult hepatitis B vaccine approved for individuals 18 years of age and older, known for its two-dose regimen and higher efficacy. The company also utilizes its proprietary TLR9 agonist adjuvant, CpG 1018, which enhances immune response and has been used in multiple COVID-19 vaccines. Dynavax is advancing a pipeline of vaccine candidates, including those for shingles, tetanus, diphtheria, pertussis, and plague.

Dynavax Technologies has a focused global presence, primarily in North America and Europe. Its U.S. operations, headquartered in Emeryville, California, drive research, development, and commercialization. A European office in Germany supports market access and commercial activities. The CpG 1018 adjuvant is supplied globally to partners for use in various vaccine development programs. The company also engages in global clinical trials and collaborations.

Dynavax's brand reputation has been shaped by the commercial success of HEPLISAV-B, its role in COVID-19 vaccine development, and the recent acquisition news. HEPLISAV-B has captured a significant market share and has seen sustained growth. Dynavax's CpG 1018 adjuvant was used in multiple COVID-19 vaccines globally. The agreement for Sanofi to acquire Dynavax for $2.2 billion reflects positively on the company's value. Engagement with activist investor Deep Track Capital brought scrutiny to the company's strategic direction.

Dynavax Technologies Corporation has a broad base of institutional support, with 555 institutional owners and shareholders collectively holding 154,007,358 shares as of July 21, 2025. Major institutional owners include BlackRock, Inc., Deep Track Capital, LP, and Vanguard Group Inc. Approximately 66.02% of the company's stock is owned by Institutional Investors, 13.92% by Insiders, and 20.06% by Public Companies and Individual Investors.